Newbridge Financial Services Group, Inc. Cardiff Oncology, Inc. Transaction History

Newbridge Financial Services Group, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Mar 28, 2024	SELL	$0.96 - $1.55 $94 - $151	-98 Reduced 85.22%	17 $0
Q3 2022 Oct 13, 2022	SELL	$1.54 - $3.21 $1,102 - $2,298	-716 Reduced 86.16%	115 $0
Q3 2021 Oct 27, 2021	BUY	$5.01 - $7.58 $3,672 - $5,556	733 Added 747.96%	831 $6,000
Q1 2021 Sep 07, 2021	BUY	$9.1 - $19.57 $891 - $1,917	98 New	98 $1,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $184M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.